

### REMARKS

Claims 24-30 remain pending.

The amendments to independent claim 24 are supported in the original disclosure at page 13, lines 15-20, corresponding to paragraph 0058 of U.S. Patent Publication No. 2007/0060544. The preamble of claim 27 has been amended to make it consistent with the preambles of the other dependent claims. Accordingly, Applicant respectfully requests approval and entry of the above amendments.

Claim 24 stands rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 3,840,597 to Moore et al. Claims 25-30 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Moore in view of U.S. Patent No. 5,756,546 to Pirotte et al.

Applicant respectfully traverses this rejection.

Applicant respectfully submits that the applied art does not specifically disclose the claimed method for treating inflammation and pain with low toxicity using the more potent compounds defined in claim 1. Although Moore generally mentions that its compounds have an anti-inflammatory activity and that some of the compounds have anti-pain activity, it would not have been obvious for a person of ordinary skill in the art to obtain the compounds defined in claim 1 with both anti-inflammatory activity and anti-pain activity, and use them in treating both inflammation and pain, especially considering Applicant's earlier showing that some of the compounds disclosed in Moore have no anti-inflammation activity or no anti-pain activity.

Additionally, there is no showing that the compounds disclosed in Moore would have the claimed low toxicity level now claimed in claim 24. As described in the background section of

10/541,058  
In re SUN, et al.

the present application, recently there has been reported cases of severe liver damage associated with conventional non-steroid anti-inflammatory drugs. The present invention provides the highly desired and unexpected result of providing excellent therapeutic effects with low harmful side-effects.

For these reasons, Applicant respectfully requests reconsideration and withdrawal of the Section 102 and 103 rejections.

***Conclusion***

It is submitted that the present application is now in condition for examination on its merits, and action to that fact is earnestly solicited. In the event the Examiners discover matters which might be resolved by further discussion, they are invited to contact the undersigned at the local telephone number listed below.

The Patent Office is authorized to charge any fees, including extra claim and extension fees, to our Deposit Account No. 50-0548.

Applicant respectfully requests early and favorable action.

Respectfully submitted,

By:



Matthew W. Stavish  
Registration No. 36,286  
Tel. No. (301) 896 0600  
Fax. No. (301) 896-0607

Berenato, White & Stavish, LLC  
6550 Rock Spring Drive  
Suite 240  
Bethesda, MD 20817